Skip to main content

19656 Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

NCT03611738

Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Associated Conditions

Lung Cancer

Principal Investigator

Sponsor

Moffitt Cancer Center

The main purpose of this study is to find out what effects (good and bad) ceritinib (Zykadia) used in combination with docetaxel (Taxotere) will have on you and your cancer.

This study is currently enrolling.